Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BONESUPPORT HOLDING AB ( (SE:BONEX) ) just unveiled an announcement.
BONESUPPORT HOLDING AB reported strong growth in the US market for Q2 2025, with net sales increasing by 29% and significant sales growth in North America. The company’s CERAMENT G product continues to gain traction, supported by clinical evidence and increased awareness of its benefits in treating bone infections. The US Centers for Medicare & Medicaid Services proposed extended cost coverage for CERAMENT G, indicating its growing importance in orthopedic treatments. The company is also undergoing a leadership transition, with a new CEO set to take over in September 2025.
More about BONESUPPORT HOLDING AB
BONESUPPORT HOLDING AB operates in the medical technology industry, focusing on innovative bone graft substitutes. Their primary product, CERAMENT G, is used for bone healing and local antibiotic elution, targeting bone infections and fracture-related infections, particularly in diabetic patients.
Average Trading Volume: 202,755
Current Market Cap: SEK19.48B
For a thorough assessment of BONEX stock, go to TipRanks’ Stock Analysis page.